Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.39 +0.21 (+0.52%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,221,119
Open 40.09
Bid (Size) 40.35 (1)
Ask (Size) 40.48 (27)
Prev. Close 40.18
Today's Range 39.87 - 40.45
52wk Range 39.23 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.86%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
These companies sport strong performance histories and plenty of promise. 
Via The Motley Fool
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
These three spinoffs are already profitable. 
Via The Motley Fool

Performance

YTD
-21.21%
-21.21%
1 Month
-3.26%
-3.26%
3 Month
-21.01%
-21.01%
6 Month
-7.85%
-7.85%
1 Year
-24.19%
-24.19%

More News

Read More
This Cancer Drug Candidate Could Be a Hit for Pfizer
Via The Motley Fool
Can This New Drug Boost Pfizer's Stock?
Via The Motley Fool
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Check Out What Whales Are Doing With PFE
Via Benzinga
7 Blue-Chip Stocks to Buy for Capital Preservation
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Via The Motley Fool
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Via MarketBeat
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
Via Benzinga
7 High-Yield Dividend Stocks to Compete Against Rising Yields
Via InvestorPlace
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Via Investor's Business Daily
Pfizer Has Another Blockbuster on the Horizon, but That's Not All
Via The Motley Fool
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
Via MarketBeat
Exposures Product Safety
Insiders Selling Pfizer And 2 Other Stocks
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.